RESUMO
The progressive use of noninvasive tests (NITs) has changed the way hepatologists diagnose and manage patients with chronic liver disease, mainly because of their easiness to use and the ability to be repeated during follow-up. Liver stiffness measurement is the NIT with more scientific evidence. NITs have demonstrated to be useful to detect not only liver fibrosis but also the presence of clinically significant portal hypertension. Moreover, current evidence supports they can also be useful to evaluate the prognosis of patients with chronic liver disease.
Assuntos
Técnicas de Imagem por Elasticidade , Hipertensão Portal , Cirrose Hepática , Humanos , Hipertensão Portal/diagnóstico , Hipertensão Portal/etiologia , Hipertensão Portal/fisiopatologia , Cirrose Hepática/diagnóstico , Cirrose Hepática/complicações , Cirrose Hepática/fisiopatologia , Fígado/diagnóstico por imagem , Fígado/patologia , Fígado/fisiopatologia , Prognóstico , Varizes Esofágicas e Gástricas/diagnóstico , Varizes Esofágicas e Gástricas/etiologiaRESUMO
BACKGROUND: To provide patients the chance of accepting curative transjugular intrahepatic portosystemic shunt (TIPS) rather than palliative treatments for portal hypertension-related variceal bleeding and ascites, we aimed to assess hepatic-associated vascular morphological change to improve the predictive accuracy of overt hepatic encephalopathy (HE) risks. METHODS: In this multicenter study, 621 patients undergoing TIPS were subdivided into training (413 cases from 3 hospitals) and external validation datasets (208 cases from another 3 hospitals). In addition to traditional clinical factors, we assessed hepatic-associated vascular morphological changes using maximum diameter (including absolute and ratio values). Three predictive models (clinical, hepatic-associated vascular, and combined) were constructed using logistic regression. Their discrimination and calibration were compared to test the necessity of hepatic-associated vascular assessment and identify the optimal model. Furthermore, to verify the improved performance of ModelC-V, we compared it with four previous models, both in discrimination and calibration. RESULTS: The combined model outperformed the clinical and hepatic-associated vascular models (training: 0.814, 0.754, 0.727; validation: 0.781, 0.679, 0.776; p < 0.050) and had the best calibration. Compared to previous models, ModelC-V showed superior performance in discrimination. The high-, middle-, and low-risk populations displayed significantly different overt HE incidence (p < 0.001). Despite the limited ability of pre-TIPS ammonia to predict overt HE risks, the combined model displayed a satisfactory ability to predict overt HE risks, both in the low- and high-ammonia subgroups. CONCLUSION: Hepatic-associated vascular assessment improved the predictive accuracy of overt HE, ensuring curative chances by TIPS for suitable patients and providing insights for cirrhosis-related studies.
Assuntos
Encefalopatia Hepática , Derivação Portossistêmica Transjugular Intra-Hepática , Humanos , Encefalopatia Hepática/etiologia , Masculino , Feminino , Pessoa de Meia-Idade , Cirrose Hepática/complicações , Hipertensão Portal , Estudos Retrospectivos , Idoso , Valor Preditivo dos Testes , Fígado/patologia , Fígado/irrigação sanguíneaRESUMO
BACKGROUND: Meso-Rex bypass is the surgical intervention of choice for children with extrahepatic portal vein obstruction (EHPVO). Patency of Rex vein, umbilical recessus of the portal vein, is a prerequisite for this surgery. Conventional diagnostic modalities poorly detect patency, while transjugular wedged hepatic vein portography (WHVP) accurately detects patency in 90%. OBJECTIVES: We aimed to assess Rex vein patency and portal vein branching pattern in children with EHPVO using transjugular WHVP and to identify factors associated with Rex vein patency. METHODS: Transjugular WHVP was performed in 31 children with EHPVO by selective cannulation of left and right hepatic veins. Rex vein patency, type of intrahepatic portal venous anatomy (Types A-E), and factors associated with patency of Rex vein were studied. RESULTS: The patency of Rex recess on transjugular WHVP was 29%. Complete obliteration of intrahepatic portal venous radicles was the commonest pattern (Type E, 38.7%) while Type A, the favorable anatomy for meso-Rex bypass, was seen in only 12.9%. Patency of the Rex vein, but not the anatomical pattern, was associated with younger age at evaluation (patent Rex: 6.6 ± 4.9 years vs. nonpatent Rex: 12.7 ± 3.9 years, p = 0.001). Under-5-year children had a 12 times greater chance of having a patent Rex vein (odds ratio: 12.22, 95% confidence interval: 1.65-90.40, p = 0.004). Patency or pattern was unrelated to local factors like umbilical vein catheterization, systemic thrombophilia, or disease severity. CONCLUSION: Less than one-third of our pediatric EHPVO patients have a patent Rex vein. Younger age at evaluation is significantly associated with Rex vein patency.
Assuntos
Veias Hepáticas , Veia Porta , Portografia , Grau de Desobstrução Vascular , Humanos , Veia Porta/diagnóstico por imagem , Veia Porta/cirurgia , Criança , Feminino , Masculino , Pré-Escolar , Veias Hepáticas/diagnóstico por imagem , Portografia/métodos , Adolescente , Lactente , Hipertensão Portal/diagnóstico por imagem , Hipertensão Portal/cirurgiaRESUMO
Cirrhosis is considered a growing cause of morbidity and mortality, which represents a significant public health problem. Currently, there is no effective treatment to reverse cirrhosis. Treatment primarily centers on addressing the underlying liver condition, monitoring, and managing portal hypertension-related complications, and evaluating the potential for liver transplantation in cases of decompensated cirrhosis, marked by rapid progression and the emergence of complications like variceal bleeding, hepatic encephalopathy, ascites, malnutrition, and more. Malnutrition, a prevalent complication across all disease stages, is often underdiagnosed in cirrhosis due to the complexities of nutritional assessment in patients with fluid retention and/or obesity, despite its crucial impact on prognosis. Increasing emphasis has been placed on the collaboration of nutritionists within hepatology and Liver transplant teams to deliver comprehensive care, a practice that has shown to improve outcomes. This review covers appropriate screening and assessment methods for evaluating the nutritional status of this population, diagnostic approaches for malnutrition, and context-specific nutrition treatments. It also discusses evidence-based recommendations for supplementation and physical exercise, both essential elements of the standard care provided to cirrhotic patients.
Assuntos
Varizes Esofágicas e Gástricas , Hipertensão Portal , Desnutrição , Humanos , Estado Nutricional , Varizes Esofágicas e Gástricas/complicações , Hemorragia Gastrointestinal/etiologia , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Cirrose Hepática/terapia , Hipertensão Portal/etiologia , Desnutrição/diagnóstico , Desnutrição/etiologia , Desnutrição/terapia , Avaliação NutricionalRESUMO
Accurate assessment of portacaval pressure gradient (PCG) in patients with portal hypertension (PH) is of great significance both for diagnosis and treatment. This study aims to develop a noninvasive method for assessing PCG in PH patients and evaluate its accuracy and effectiveness. This study recruited 37 PH patients treated with transjugular intrahepatic portosystemic shunt (TIPS). computed tomography angiography was used to create three dimension (3D) models of each patient before and after TIPS. Doppler ultrasound examinations were conducted to obtain the patient's portal vein flow (or splenic vein and superior mesenteric vein). Using computational fluid dynamics (CFD) simulation, the patient's pre-TIPS and post-TIPS PCG was determined by the 3D models and ultrasound measurements. The accuracy of these noninvasive results was then compared to clinical invasive measurements. The results showed a strong linear correlation between the PCG simulated by CFD and the clinical invasive measurements both before and after TIPS (R2 = 0.998, P < 0.001 and R2 = 0.959, P < 0.001). The evaluation accuracy of this noninvasive method reached 94 %, and the influence of ultrasound result errors on the numerical accuracy was found to be marginal if the error was less than 20 %. Furthermore, the information about the hemodynamic environment in the portal system was obtained by this numerical method. Spiral flow patterns were observed in the portal vein of some patients. In a conclusion, this study proposes a noninvasive numerical method for assessing PCG in PH patients before and after TIPS. This method can assist doctors in accurately diagnosing patients and selecting appropriate treatment plans. Additionally, it can be used to further investigate potential biomechanical causes of complications related to TIPS in the future.
Assuntos
Hipertensão Portal , Derivação Portossistêmica Transjugular Intra-Hepática , Humanos , Derivação Portossistêmica Transjugular Intra-Hepática/efeitos adversos , Derivação Portossistêmica Transjugular Intra-Hepática/métodos , Hidrodinâmica , Veia Porta/diagnóstico por imagem , Hipertensão Portal/diagnóstico por imagem , HemodinâmicaRESUMO
BACKGROUND: Alcohol-related liver disease (ARLD) is often diagnosed at a late stage when mortality is unacceptably high. Earlier identification of ARLD may lead to reduced alcohol intake, participation in hepatocellular carcinoma surveillance and reduction in liver-related morbidity and mortality. People with alcohol use disorder (AUD) are at highest risk of ARLD. The aim of this systematic review was to understand the yield of proactive screening for ARLD amongst high-risk groups. METHODS: Embase, Medline, Scopus and grey literature were searched for studies describing proactive assessment for alcohol-related liver disease in people with a history of alcohol excess or diagnosed AUD. Outcomes of interest were fibrosis and cirrhosis detection rates, clinical outcomes, portal hypertension evaluation, attendance at follow-up and cost-effectiveness. RESULTS: Fifteen studies were identified for inclusion from 1115 returned by the search. Four key settings for patient engagement were identified as inpatient addiction services, outpatient addiction services, general acute hospital admissions and community outreach. Of these, acute hospital admissions were the highest yield for cirrhosis at 10.8%-29.6% and community outreach the lowest was 1.2%-2.3%. CONCLUSIONS: Targeted fibrosis assessment of high-risk populations for ARLD is feasible to conduct and identifies a proportion of patients at risk of advanced liver disease. The highest yield is amongst inpatients admitted with AUD. Prospective work is needed to establish which are the most effective and acceptable screening methods and the impact on long-term outcomes.
Assuntos
Hepatopatias Alcoólicas , Humanos , Hepatopatias Alcoólicas/diagnóstico , Hepatopatias Alcoólicas/epidemiologia , Alcoolismo/complicações , Programas de Rastreamento/métodos , Fatores de Risco , Análise Custo-Benefício , Hipertensão Portal/diagnósticoRESUMO
INTRODUCTION: Systemic therapies have been associated with clinically significant events (CSEs) in patients with unresectable hepatocellular carcinoma (uHCC). We evaluated the incidence of CSEs (bleeding, clotting, encephalopathy, and portal hypertension), and their impact on healthcare resource utilization (HCRU) and costs, in patients with uHCC treated with first-line (1L) atezolizumab plus bevacizumab (A + B), lenvatinib (LEN), or sorafenib (SOR) in the USA. METHODS: A retrospective cohort study was performed using medical/pharmacy claims from Optum® Clinformatics® Data Mart. Patients diagnosed with HCC who initiated 1L A + B between June 01, 2020 and December 31, 2020 or LEN/SOR between January 01, 2016 and May 31, 2020 were included. Outcomes included incidence rates of CSEs, HCRU, and costs. Subgroup analysis was performed in patients with no CSEs or ≥ 1 CSE. RESULTS: In total, 1379 patients were selected (A + B, n = 271; LEN, n = 217; SOR, n = 891). Clotting (incidence rate per 100 patient-years [PY] 94.9) and bleeding (88.1 per 100 PY) were the most common CSEs in the A + B cohort. The most common CSEs in the LEN cohort were clotting (78.6 per 100 PY) and encephalopathy (66.3 per 100 PY). Encephalopathy (73.0 per 100 PY) and portal hypertension (72.3 per 100 PY) were the most common CSEs in the SOR cohort. Mean total all-cause healthcare costs per patient per month (PPPM) were $32,742, $35,623, and $29,173 in the A + B, LEN, and SOR cohorts, respectively. Mean total all-cause healthcare costs PPPM were higher in patients who had ≥ 1 CSE versus those who did not (A + B $34,304 versus $30,889; LEN $39,591 versus $30,621; SOR $31,022 versus $27,003). CONCLUSION: Despite improved efficacy of 1L systemic therapies, CSEs remain a concern for patients with uHCC, as well as an economic burden to the healthcare system. Newer treatments that reduce the risk of CSEs, while improving long-term survival in patients with uHCC, are warranted.
Certain treatments for liver cancer can cause serious side effects, including bleeding, blood clots, brain injury (encephalopathy), or increased blood flow to the liver (portal hypertension). We used an insurance database to find out how often these events, known as clinically significant events, occurred in people with liver cancer who were given treatments that target the immune system (immunotherapy) or specific proteins involved in cancer growth and survival (targeted therapy). The study included 1379 patients treated with atezolizumab (immunotherapy) plus bevacizumab (targeted therapy), or lenvatinib or sorafenib alone (both targeted therapies), as their first treatment. Clotting and bleeding were the most common clinically significant events in patients treated with atezolizumab plus bevacizumab, whereas clotting and encephalopathy were the most common clinically significant events with lenvatinib, and encephalopathy and portal hypertension were the most common clinically significant events with sorafenib. On average, for every 100 patients treated for 1 year, there were more than 50 of each of these events. Average healthcare costs per patient per month ranged from around $29,000 to around $36,000 in the three different treatment groups, and were higher in people who had at least one clinically significant event. These results suggest that clinically significant events are common in people with liver cancer who are given various types of treatment. As well as raising concerns for patient safety, these events result in higher costs to healthcare systems. Therefore, newer treatments that are less likely to cause clinically significant events, while improving survival in patients with liver cancer, are needed.
Assuntos
Encefalopatias , Carcinoma Hepatocelular , Hipertensão Portal , Neoplasias Hepáticas , Compostos de Fenilureia , Quinolinas , Humanos , Carcinoma Hepatocelular/tratamento farmacológico , Incidência , Neoplasias Hepáticas/tratamento farmacológico , Estudos Retrospectivos , Sorafenibe , HemorragiaRESUMO
PURPOSE OF REVIEW: The result of ongoing liver injury - and disease, regardless of cause - is fibrosis, and fibrosis appears to be a critically important result of ongoing injury. Further, in a number of different liver diseases, the presence of fibrosis has prognostic value. Therefore, the assessment of fibrosis is of critical clinical importance. Given the importance of fibrosis, there has been a rapid evolution in the use of noninvasive liver tests. This review highlights a number of the core principles surrounding. RECENT FINDINGS: The use of noninvasive test has progressed rapidly over the last decade and data are rapidly accumulating. New terminology has been adapted by the American Association for the Study of Liver Disease (AASLD) for noninvasive assessment of liver disease and termed 'NILDA' (Non-Invasive Liver Disease Assessment). Blood based such as APRI and or FIB-4 and imaging tests such as liver stiffness measurement (LSM) have moderate to high degrees of accuracy for detection of advanced liver fibrosis (≥ F2) and even higher accuracy for detection of severe fibrosis (F4 or cirrhosis). NILDA are particularly effective at the ends of the liver disease spectrum. For example, a very low LSM (less than 7âkPa) essentially excludes significant fibrosis or portal hypertension, and a very high LSM (> 25âkPa) makes significant fibrosis with portal hypertension (cirrhosis) highly likely. SUMMARY: NILDA are currently front and center in terms of assessment of the severity of liver disease. In all patients with known or suspected liver disease, noninvasive blood tests, including APRI and or FIB-4, should be the initial choice to assess the severity of liver fibrosis and/or portal hypertension. In most patients, these tests should be followed with imaging evaluation. The most commonly available imaging is LSM, which appears to be more accurate in predicting fibrosis severity, and is superior to blood tests in the assessment of portal hypertension. In situations in which there is diagnostic uncertainly, liver biopsy with or without HVPG remains an important consideration.
Assuntos
Técnicas de Imagem por Elasticidade , Hipertensão Portal , Humanos , Técnicas de Imagem por Elasticidade/métodos , Cirrose Hepática/complicações , Cirrose Hepática/diagnóstico , Fígado/diagnóstico por imagem , Fígado/patologia , Hipertensão Portal/diagnóstico , Hipertensão Portal/etiologia , Prognóstico , FibroseRESUMO
OBJECTIVE: Examine portal hypertension (PHT) impact on postoperative and survival outcomes in hepatocellular carcinoma (HCC) patients after liver resection (LR), specifically exploring distinctions between indirect signs and invasive measurements of PHT. BACKGROUND: PHT has historically discouraged LR in individuals with HCC due to the elevated risk of morbidity, including liver decompensation (LD). METHODS: A systematic review was conducted using 3 databases to identify prospective-controlled and matched cohort studies until December 28, 2022. Focus on comparing postoperative outcomes (mortality, morbidity, and liver-related complications) and overall survival in HCC patients with and without PHT undergoing LR. Three meta-analysis models were utilized: for aggregated data (fixed-effects inverse variance model), for patient-level survival data (one-stage frequentist meta-analysis with gamma-shared frailty Cox proportional hazards model), and for pooled data (Freeman-Tukey exact and double arcsine method). RESULTS: Nine studies involving 1124 patients were analyzed. Indirect signs of PHT were not significantly associated with higher mortality, overall complications, PHLF or LD. However, LR in patients with hepatic venous pressure gradient (HVPG) ≥10 mm Hg significantly increased the risk of overall complications, PHLF, and LD. Despite elevated risks, the procedure resulted in a 5-year overall survival rate of 55.2%. Open LR significantly increased the risk of overall complications, PHLF, and LD. Conversely, PHT did not show a significant association with worse postoperative outcomes in minimally invasive LR. CONCLUSIONS: LR in the presence of indirect signs of PHT poses no increased risk of complications. Yet, in HVPG ≥10 mm Hg patients, LR increases overall morbidity and liver-related complications risk. Transjugular HVPG assessment is crucial for LR decisions. Minimally invasive approach seems to be vital for favorable outcomes, especially in HVPG ≥10 mm Hg patients.
Assuntos
Carcinoma Hepatocelular , Hepatectomia , Hipertensão Portal , Neoplasias Hepáticas , Humanos , Hipertensão Portal/complicações , Neoplasias Hepáticas/cirurgia , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/complicações , Carcinoma Hepatocelular/cirurgia , Carcinoma Hepatocelular/mortalidade , Carcinoma Hepatocelular/complicações , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/etiologia , Estudos Prospectivos , Taxa de Sobrevida , Resultado do TratamentoAssuntos
Feminino , Humanos , Masculino , Carcinoma Hepatocelular/fisiopatologia , Cirrose Hepática/fisiopatologia , Neoplasias Hepáticas/fisiopatologia , Fígado/fisiopatologia , Carcinoma Hepatocelular/patologia , Carcinoma Hepatocelular/cirurgia , Hipertensão Portal/diagnóstico , Cirrose Hepática/patologia , Cirrose Hepática/cirurgia , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/cirurgia , Fígado/patologia , Fígado/cirurgia , Valores de Referência , Carga Tumoral , Pressão VenosaRESUMO
OBJETIVO: Medir a sensibilidade e a reprodutibilidade da ultra-sonografia na detecção de nódulos sideróticos esplênicos em pacientes esquistossomóticos, tendo a ressonância magnética como padrão de referência. MATERIAIS E MÉTODOS: Na primeira fase do trabalho, 21 pacientes portadores de esquistossomose na forma hepatoesplênica com diagnóstico de nódulos sideróticos à ressonância magnética foram submetidos a avaliação ultra-sonográfica para a determinação da sensibilidade do método. Na segunda fase, com o objetivo de avaliar a reprodutibilidade da ultra-sonografia na detecção e na quantificação de nódulos sideróticos (A: 1-5 nódulos; B: 6-20 nódulos; C: mais de 20 nódulos), outros 30 pacientes esquistossomóticos foram submetidos a avaliação ultra-sonográfica de forma cega e independente por dois observadores. A reprodutibilidade foi medida por meio da concordância entre os observadores e do teste kappa. RESULTADOS: A sensibilidade da ultra-sonografia foi de 95,2 por cento (intervalo de confiança a 95 por cento [77,3 por cento; 99,2 por cento]). A concordância entre ultra-sonografia e ressonância magnética para a detecção de nódulos sideróticos foi de 96,7 por cento (intervalo de confiança a 95 por cento [82,8 por cento; 99,9 por cento]). Para a classificação dos nódulos conforme a sua quantificação, o índice kappa demonstrou concordância interobservador substancial (kappa = 0,67). CONCLUSÃO: A ultra-sonografia é um método que apresenta elevada sensibilidade e boa precisão para a avaliação de nódulos sideróticos esplênicos.
OBJECTIVE: To evaluate ultrasound sensitivity and reproducibility as compared with magnetic resonance imaging as the gold standard in the detection of splenic siderotic nodules in schistosomal patients. MATERIALS AND METHODS: Initially, 21 patients with hepatosplenic schistosomiasis and diagnosed with splenic siderotic nodules by magnetic resonance imaging were ultrasonographically evaluated for determining the method sensitivity. In a second phase, the method reproducibility in the detection and quantification of siderotic nodules (A: 1-5 nodules; B: 6-20 nodules; C: > 20 nodules) was evaluated in 30 patients who were submitted to ultrasonography blindly and independently assessed by two observers. Interobserver agreement was measured by kappa statistics. RESULTS: Ultrasound sensitivity was 95.2 percent (95 percent confidence interval [77.3 percent; 99.2 percent]). Intermethod agreement in the detection of siderotic nodules was 96.7 percent (95 percent confidence interval [82.8 percent; 99.9 percent]). For classification of nodules according to their quantification, the kappa test demonstrated a statistically significant interobserver agreement (kappa = 0.67). CONCLUSION: Ultrasonography is highly sensitive and accurate in the assessment of splenic siderotic nodules in schistosomal patients.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso de 80 Anos ou mais , Baço/fisiopatologia , Baço , Esquistossomose/complicações , Hipertensão Portal , Hepatopatias , Hipertensão Portal/etiologia , Esquistossomose , Espectroscopia de Ressonância Magnética , HemossiderinaRESUMO
RACIONAL: Dados referentes às repercussões da obstrução extra-hepática da veia porta sobre o crescimento de crianças são escassos. OBJETIVO: Avaliar os índices antropométricos de um grupo de crianças com trombose de veia porta e hipertensão portal, acompanhadas longitudinalmente, cujos episódios de sangramento digestivo foram controlados por meio de esclerose endoscópica das varizes esofágicas. MÉTODOS: Os dados antropométricos foram obtidos retrospectivamente a partir dos prontuários de 24 pacientes. Os escores Z das relações peso para idade, altura para idade e o índice de massa corporal foram registrados na primeira consulta no serviço e na última consulta anterior ao estudo, após seguimento de 3,8 ± 2,5 anos. As duas medidas de cada paciente foram comparadas aos dados do Centro Nacional de Estatística da Saúde dos EUA e entre si. RESULTADOS: As médias dos valores de escore Z estavam dentro dos valores considerados normais para a população de referência, peso para idade: 0,042 ± 1,09 e 0,132 ± 1,29; altura para idade: 0,200 ± 1,04 e 0,466 ± 1,24 e índice de massa corporal: -0,223 ± 0,98 e -0,198 ± 0,98, para os registros na primeira e na última consulta, respectivamente. A comparação dos valores de escore Z de cada uma dessas relações, ao longo do tempo, não demonstrou diferença estatística. CONCLUSAO: O presente grupo de crianças com trombose de veia porta e hipertensão portal não apresentou atraso de crescimento durante o acompanhamento clínico.
Assuntos
Humanos , Masculino , Feminino , Lactente , Pré-Escolar , Criança , Adolescente , Crescimento/fisiologia , Hipertensão Portal/fisiopatologia , Veia Porta , Trombose Venosa/fisiopatologia , Antropometria , Endoscopia/métodos , Varizes Esofágicas e Gástricas/terapia , Hipertensão Portal/etiologia , Estudos Longitudinais , Estudos Retrospectivos , Escleroterapia/métodos , Trombose Venosa/complicaçõesRESUMO
Con el advenimiento de transductores de ultrasonido endoluminal, se han logrado importantes avances diagnósticos y terapéuticos, especialmente en el campo cardiovascular y vascular periférico. Aunque su uso se ha extendido, no tenemos conocimiento de su utilidad en la evalucaión de prótesis portosistémicas intrahepáticas colocadas por vía transyugular (TIPS). Informamos sobre una mujer de 40 años de edad a quien se realizó ultrasonido endoluminal de la prótesis intrahepática a los seis meses de colocada ésta. Se documentó un diámetro interior en la prótesis de 8.6 mm y de téjido fibroso de neoformación de 1.4 milímetros
Assuntos
Adulto , Humanos , Feminino , Derivação Portossistêmica Cirúrgica/reabilitação , Hipertensão Portal/cirurgia , Ultrassonografia de Intervenção , Varizes Esofágicas e Gástricas/cirurgiaRESUMO
A esplenectomia subtotal vem sendo estudada experimentalmente desde 1981 e aplicada à terapêutica da hipertensäo portal esquistossomática, desde 1984. O autor introduziu duas técnicas cirúrgicas para o tratamento dessa afecçäo: a esplenectomia subtotal combinada à anastomose esplenorrenal centralizada e a esplenectomia subtotal associada à desconexäo porta-varizes. Os bons resultados obtidos com ambas as alternativas terapêuticas têm sido verificados, em parte, através de exames imaginológicos, tais como ultra-som, tomografia computadorizada e cintilografia. Este artigo apresenta a avaliaçäo imaginológica dessas cirurgias.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Esquistossomose/cirurgia , Esplenectomia , Derivação Esplenorrenal Cirúrgica , Cintilografia , Tomografia Computadorizada por Raios X , Ultrassonografia , Hipertensão Portal/cirurgia , Brasil , Varizes Esofágicas e Gástricas/cirurgiaRESUMO
Ultrasonography can reveal most of the manifestations of portal hypertension complicating hepatosplenic, schistosomiasis. However, direct demonstration of gastroesophageal varices by ultrasonography is still very difficult. An attempt was done to correlate sonographic features of portal hypertension with the degree of fibrosis to screen patients having varices and predicting their chance of bleeding. The results obtained were found to be consistent with the esophagogastric endoscopy and with history of hematemesis. Four parameters were used, size of spleen, degree of periportal fibrosis, presence of collaterals and portal vein diameter. A pilot field survey was also done adopting the same principle